IMUX Stock Summary and Trading Ideas (Immunic | NASDAQ:IMUX)

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Immunic trades on the NASDAQ stock market under the symbol IMUX.

As of December 17, 2025, IMUX stock price declined to $0.58 with 1,193,609 million shares trading.

IMUX has a beta of 0.94, meaning it tends to be less sensitive to market movements. IMUX has a correlation of 0.05 to the broad based SPY ETF.

IMUX has a market cap of $69.77 million. This is considered a Micro Cap stock.

In the last 3 years, IMUX traded as high as $3.17 and as low as $.56.

The top ETF exchange traded funds that IMUX belongs to (by Net Assets): VTI, VXF, IWC.

IMUX has underperformed the market in the last year with a price return of -47.7% while the SPY ETF gained +12.0%. IMUX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -28.8% and -11.0%, respectively, while the SPY returned +2.2% and -1.3%, respectively.

IMUX support price is $.57 and resistance is $.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMUX shares will trade within this expected range on the day.